Introduction/Background

More than 75% of individuals with ovarian cancer (OC) are diagnosed at an advanced stage, given that early-stage disease is usually asymptomatic. Epigenetics studies are emerging in cancer research and diagnostics with encouraging outcomes. Recent developments in large-scale DNA methylation profiling have shown that those changes are at the very early stage of carcinogenesis, indicating that the detection of such markers would drastically increase patient outcome. In OC, that would potentially represent early detection for the majority of patients. Here, we (1) investigated a large-scale methylation landscape of OC, (2) devised a predictive model based on the discovered targets, and (3) sought to validate its performance on independent external cohorts.

Methodology

Fresh-frozen tissues were collected from 29 OC patients and 14 benign pelvic mass patients. Samples were submitted to global DNA methylation profiling, comprising of ~850,000 targets. For the design of the predictive model we performed: (1) univariate linear model; (2) LASSO-penalized multivariate analysis; (3) cross-validation; and (4) group assignment by centroid approach followed by principal component analysis (PCA). The predictive model was trained with our own samples and validated in 2 external cohorts.

Results

We identified 21 targets that showed a clear distinction for the OC patient group, with clustering analysis showing two independent groups. Furthermore, the two main components explained 66% of the variance shown by PCA. The validation of our model in 2 independent cohorts showed classification concordance of 81.1% and 85.2%, respectively.

Conclusion

Our findings showed that OC presents an unique methylation landscape represented by a signature of 21 targets. Our predictive model algorithm showed considerable concordance with external cohorts. Noteworthy, due to the relatively small cohort used to train our model, we are currently collecting more samples to further improve its prediction efficiency, which may be relevant in diagnostic settings.

Trophoblastic diseases

2022-RA-701-ESGO

ELUCIDATING MECHANISMS UNDERLYING METHOTREXATE RESISTANCE VIA QUANTITATIVE PROTEOMICS ANALYSIS OF GTN PATIENT SAMPLES AND CHORIOCARCINOMA CELL LINES: A CRUCIAL ROLE FOR SERINE METABOLISM

1Panagista Ntavelou, 1Marina Georgiou, 1Geoffrey Maher, 1Rajat Roy, 1Sija Yu, 1Paul Ajuh, 1Baljeet Kaur, 1Neil Horowitz, 1Ross S Berkowitz, 1Kevin Elias, 1Michael J Seckl, 1Olivier E Pardo, 2Division of Cancer, Department of Surgery and Cancer, Imperial College, London, UK; 2Trophoblastic Tumour Screening and Treatment Centre, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK; 3Gemini Biosciences, Liverpool, UK; 4Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

10.1136/ijgc-2022-ESGO.904

Abstract 2022-RA-1697-ESGO Figure 1

Conclusion Low ALI was associated with higher perioperative complications and poorer survival in ovarian cancer. The utility of preoperative ALI as a prognostic marker in ovarian cancer should be assessed in prospective studies.

Abstract 2022-RA-1709-ESGO

A PREDICTIVE MODEL FOR DETECTION OF EPITHELIAL OVARIAN CANCER BASED ON METHYLATION LANDSCAPE

1Douglas Nogueira Perez Oliveira, 2Claus Høgdall, 1Estrid Høgdall. 1Dept. of Pathology, Herlev og Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark; 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

10.1136/ijgc-2022-ESGO.903

Introduction/Background

Choriocarcinoma is an aggressive type of Gestational Trophoblastic Neoplasia (GTN). Patients with low-risk GTN following a molar pregnancy frequently commence therapy with single-agent methotrexate (MTX). Unfortunately, many develop resistance (MTX-R) and require either another single agent or more toxic combination agent chemotherapy to achieve remission. Understanding the molecular mechanisms of MTX-R may identify interventions to prevent or reverse this.

Methodology

We employed proteomics profiling to identify changes that accompany MTX-R in post molar GTN patient samples and in choriocarcinoma cell lines that were either MTX sensitive (MTX-S) or resistant (MTX-R).

Results

Quantitative mass spectrometry (MS) analysis revealed that the de novo serine synthesis pathway was one of the most downregulated pathways both in the MTX-R patients and in the resistant choriocarcinoma cell line. Decreased glucose-derived serine synthesis is supported by our findings that choriocarcinoma MTX-R cells have a less active glycolytic pathway. Concomitant de novo serine synthesis inhibition and treatment could improve therapeutic response in patients with MTX-R.

Conclusion

Upon MTX-R, choriocarcinoma cells favor redirection of serine to GSH production and this may help with combating chemotherapy-induced reactive oxygen species (ROS) accumulation and hence participate in the resistant phenotype. In contrast, MTX-sensitive cells utilize serine for nucleotide synthesis and the maintenance of proliferation. Hence, targeting upstream pathways or molecules that block the synthesis of serine in combination with or without MTX treatment could improve therapeutic response in patients with MTX resistance.